A phase I trial to evaluate Antibody-Coupled T-cell Receptor (ACTR) platform in Non-Hodgkin Lymphoma (NHL) patients who have failed to respond or relapsed following treatment with chemotherapy plus rituximab

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 02 Sep 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ATTCK 20 (Primary) ; Rituximab
Indications Non-Hodgkin's lymphoma
Focus Adverse reactions

Most Recent Events

16 Dec 2015 New trial record
14 Dec 2015 According to an Unum Therapeutics media release, the company plans to file an IND with the US FDA and to begin clinical testing in 2016.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight